Posted by: BooDog
In reply to: scottsmith who wrote msg# 222721 Date:3/29/2018 11:24:09 AM
Post #222733 of 222739
The Prurisol Phase 2b clinical trial in Moderate-to-Severe Psoriasis remains blinded at present. Once the full dataset has been unblinded, received and reviewed, the Company will release the results. A novel psoriasis drug, particularly one that is oral, safe and effective, would be well-received by clinical practitioners and patients alike, and would likely command significant market value.
Brilacidin-OM: Sachet Development
While already competitively advantaged as an oral rinse versus IV drug delivery, Innovation Pharma is actively exploring developing Brilacidin-OM as a sachet—an industry term for a small packet, similar to a common sugar packet. A sachet is easily transported and is less expensive than a liquid formulation and should be considerably less costly than a sterile IV drug for SOM. Add in the facility costs of multiple IV infusions per week over a treatment period of 6-7 weeks, and the cost can easily escalate (e.g. 1 hour of infusion, 5 days a week), which can severely limits a drug’s commercial prospects, especially if there are far less expensive alternatives. With a sachet, the Company envisions patients simply mixing the contents of the Brilacidin-OM sachet with water for a quick-and-easy treatment at home or on-the-go for the prevention of SOM.
https://www.ipharminc.com/press-release/2018/...-mucositis
Innovation Pharmaceuticals Concludes Successful Phase 2a Trial of Kevetrin for Ovarian Cancer; Intra-Tumor Modulation of p53 Observed
today announces the closure of its Phase 2a clinical trial (see NCT03042702) of Kevetrin for the treatment of late-stage Ovarian Cancer (OC). The Company initiated the trial for the purpose of demonstrating modulation of the key tumor-suppressor protein p53, which was achieved in analysis of the first patients at the lowest dose of Kevetrin (see December 27, 2017 press release).
https://www.ipharminc.com/press-release/2018/...3-observed
Guess I've been following the bouncing ball.
Continuing to accumulate for the massive gap up this sees on good data. I've been swinging this for quite some time. It's about to get real imo.
$IPIX
Like this post...
Round and round they go.
In reply to: scottsmith who wrote msg# 222721 Date:3/29/2018 11:24:09 AM
Post #222733 of 222739
The Prurisol Phase 2b clinical trial in Moderate-to-Severe Psoriasis remains blinded at present. Once the full dataset has been unblinded, received and reviewed, the Company will release the results. A novel psoriasis drug, particularly one that is oral, safe and effective, would be well-received by clinical practitioners and patients alike, and would likely command significant market value.
Brilacidin-OM: Sachet Development
While already competitively advantaged as an oral rinse versus IV drug delivery, Innovation Pharma is actively exploring developing Brilacidin-OM as a sachet—an industry term for a small packet, similar to a common sugar packet. A sachet is easily transported and is less expensive than a liquid formulation and should be considerably less costly than a sterile IV drug for SOM. Add in the facility costs of multiple IV infusions per week over a treatment period of 6-7 weeks, and the cost can easily escalate (e.g. 1 hour of infusion, 5 days a week), which can severely limits a drug’s commercial prospects, especially if there are far less expensive alternatives. With a sachet, the Company envisions patients simply mixing the contents of the Brilacidin-OM sachet with water for a quick-and-easy treatment at home or on-the-go for the prevention of SOM.
https://www.ipharminc.com/press-release/2018/...-mucositis
Innovation Pharmaceuticals Concludes Successful Phase 2a Trial of Kevetrin for Ovarian Cancer; Intra-Tumor Modulation of p53 Observed
today announces the closure of its Phase 2a clinical trial (see NCT03042702) of Kevetrin for the treatment of late-stage Ovarian Cancer (OC). The Company initiated the trial for the purpose of demonstrating modulation of the key tumor-suppressor protein p53, which was achieved in analysis of the first patients at the lowest dose of Kevetrin (see December 27, 2017 press release).
https://www.ipharminc.com/press-release/2018/...3-observed
Guess I've been following the bouncing ball.
Continuing to accumulate for the massive gap up this sees on good data. I've been swinging this for quite some time. It's about to get real imo.
$IPIX
Like this post...
Quote:
bradfordbros Thursday, 03/29/18 11:02:20 AM
Re: scottsmith post# 222721 0
Post # of 222728
There's nothing quick about drug trials and nothing quick about updates. We've been spoilt by Leo but now it's serious time when experienced knowledgeable biotech investors wait patiently to be updated.
Respond | View Replies (1)
Round and round they go.
2
